---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-068512"
form_type: "8-K"
ticker: "ALKS"
cik: "0001520262"
company_name: "Alkermes plc."
filed_at: "2026-02-25T23:59:59+00:00"
generated_at: "2026-05-16T00:15:53.065590+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Alkermes: FY2025 revenue $1.48B, GAAP EPS $1.43; 2026 guidance shows net loss from Avadel deal

## Summary
- Total revenue $1.48B in 2025; proprietary net sales up ~9% to $1.18B; LYBALVI grew 22% in Q4.
- GAAP net income $242M ($1.43 dil EPS) vs $367M in 2024; Q4 net income $49.3M.
- Closed Avadel acquisition Feb 12, 2026; used $775M cash + $1.525B term loans; expects ~$150M inventory step-up expense.
- 2026 guidance: revenue $1.73-1.84B, GAAP net loss $(115)-$(135)M, adjusted EBITDA $370-410M.
- Alixorexton Phase 3 for narcolepsy to start Q1 2026; advancing orexin pipeline for ADHD and fatigue.

## SEC filing metadata
- accession: 0001193125-26-068512
- form_type: 8-K
- ticker: ALKS
- cik: 0001520262
- company_name: Alkermes plc.
- filed_at: 2026-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1520262/000119312526068512/0001193125-26-068512-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1520262/000119312526068512/alks-20260225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-068512
- JSON: https://secwatch.observer/filing/0001193125-26-068512.json
- Plain text: https://secwatch.observer/filing/0001193125-26-068512.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.